Results 31 to 40 of about 15,139,370 (299)

Association between complaints and immune-related adverse events.

open access: yes, 2022
Association between complaints and immune-related adverse events.
Yuji Miyoshi (3172629)   +5 more
core   +1 more source

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia

open access: yesFrontiers in Pharmacology, 2019
Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors.
Roser Calvo
doaj   +1 more source

Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review

open access: yes, 2023
Immune checkpoint inhibitors have been increasingly used to treat various malignant neoplasms. Despite their superior efficacy in treating certain ones, their global immune-activation effect leads to systemic side effects, referred to as immune-related ...
Alruwaii, Zainab I.   +3 more
core   +1 more source

Treatment Outcomes of Immune-Related Cutaneous Adverse Events [PDF]

open access: yesJournal of Clinical Oncology, 2019
PURPOSE The aim of the current study was to report the efficacy of topical and systemic treatments for immune-related cutaneous adverse events (ircAEs) attributed to checkpoint inhibitors in an uncontrolled cohort of patients referred to oncodermatology clinics.
Gregory S, Phillips   +22 more
openaire   +4 more sources

Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review

open access: yes, 2022
Immune checkpoint inhibitors have been increasingly used to treat various malignant neoplasms. Despite their superior efficacy in treating certain ones, their global immune-activation effect leads to systemic side effects, referred to as immune-related ...
Elizabeth A. Montgomery   +3 more
core   +1 more source

Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series [PDF]

open access: yes, 2021
Immune checkpoint inhibitors (ICIs) targeting cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand PD-L1 are established cancer immunotherapies for solid tumor and hematologic malignancies.
Alfredomaria Lurati   +5 more
core   +2 more sources

Immune-related adverse events and the balancing act of immunotherapy [PDF]

open access: yesNature Communications, 2022
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
Michael Conroy, Jarushka Naidoo
openaire   +3 more sources

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

open access: yesJournal of Experimental & Clinical Cancer Research, 2020
The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle ...
Xiao-Hui Jia   +9 more
doaj   +1 more source

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

open access: yesThoracic Cancer, 2020
Immunotherapy for malignant tumors is a hot spot in current research and the treatment of cancer. The activation of programmed cell death receptor‐1 (PD‐1) and cytotoxic T lymphocyte‐associated antigen 4 (CTLA)‐4 relevant signaling pathway can inhibit ...
Yue Li   +10 more
doaj   +1 more source

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study

open access: yesFrontiers in Oncology, 2022
BackgroundImmune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), but there is limited evidence regarding the association between urinary incontinence and ICIs.MethodsWe described the case of a patient ...
Yizhang Hu   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy